Cosmo Bio Co

Cosmo Bio Co FCF/Debt

The Free Cash Flow to Debt Ratio of Cosmo Bio Co (3386.T) as of Nov 19, 2026 is 1,830.00 %. In the previous year, Free Cash Flow to Debt Ratio was 113.64 % — a change of 1,510.40% (higher).

FCF/Debt

1,830.00 %

YoY

1,510.40%

Last updated:

Free Cash Flow to Debt Ratio of Cosmo Bio Co is 2025 1,830.00 % . Free Cash Flow to Debt Ratio of Cosmo Bio Co was 2024 113.64 % . It decreases by 1,510.40% higher compared to the previous year.

The Cosmo Bio Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
4,285.00 JPY
Jan 1, 2019
1,935.00 JPY
Jan 1, 2020
3,690.00 JPY
Jan 1, 2021
1,810.71 JPY
Jan 1, 2022
666.67 JPY
Jan 1, 2023
2,650.00 JPY
Jan 1, 2024
113.64 JPY
Jan 1, 2025
1,830.00 JPY
The Cosmo Bio Co FCF/Debt history
YEARFCF/DebtYoY
1,830.00 %+1,510.40%
113.64 %-95.71%
2,650.00 %+297.50%
666.67 %-63.18%
1,810.71 %-50.93%
3,690.00 %+90.70%
1,935.00 %-54.84%
4,285.00 %-319.74%
-1,950.00 %-221.88%
1,600.00 %+300.00%
400.00 %-67.21%
1,220.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

Free Cash Flow to Debt Ratio of Cosmo Bio Co is 1,830.00 % in 2025.

Free Cash Flow to Debt Ratio of Cosmo Bio Co changed from 113.64 % to 1,830.00 %, representing a 1,510.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Cosmo Bio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co